### LEGISLATIVE HISTORY CHECKLIST Compiled by the NJ State Law Library

NJSA: 17:48A-1 et al

(Bone marrow transplants-Wilm's tumor--require insurers to pay)

LAWS OF: 1990

CHAPTER: 71

Bill No:

A3101

Sponsor(s):

Adubato and Pascrell

Date Introduced: February 26, 1990

Committee: Assembly: Insurance

Senate: ----

A mended during passage:

No

Date of Passage: Assembly:

March 22, 1990

Senate:

June 18, 1990

Date of Approval: July 17, 1990

Following statements are attached if available:

Sponsor statement:

Yes

Committee Statement: Assembly: Yes

Senate:

Νo

Fiscal Note:

No

Veto Message:

Νo

Message on signing:

No

Following were printed:

Reports:

No

Hearings:

No

KBG/SLJ

\$1-C.17:48-6f \$2-C.17:48A-7e \$3-C.17:48E-35.3 \$4-C.17B:26-2.1d \$5-C.17B:27-46.1e \$6-C.26:2J-4.1 \$7-Note to \$\$1-6

## P.L.1990, CHAPTER 71, approved July 17, 1990 1990 Assembly No. 3101

AN ACT requiring health insurance benefits for certain treatments for Wilm's tumor and supplementing P.L.1938, c.366 (C.17:48-1 et seq.), P.L.1940, c.74 (C.17:48A-1 et seq.), P.L.1985, c.236 (C.17:48E-1 et seq.), chapter 26 of Title 17B of the New Jersey Statutes, chapter 27 of Title 17B of the New Jersey Statutes, and P.L.1973, c.337 (C.26:2J-1 et seq.).

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

- 1. Every group or individual hospital service corporation contract providing hospital or medical expense benefits shall provide benefits to any subscriber or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the contract.
- 2. Every group or individual medical service corporation contract providing hospital or medical expense benefits shall provide benefits to any subscriber or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the contract.
- 3. Every group or individual health service corporation contract providing hospital or medical expense benefits shall provide benefits to any subscriber or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the contract.
- 4. Every individual health insurance policy providing hospital or medical expense benefits shall provide benefits to any named insured or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is

unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the policy.

- 5. Every group health insurance policy providing hospital or medical expense benefits shall provides benefits to any named insured or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the policy.
- 6. Notwithstanding any provision of law to the contrary, every health maintenance organization for which a certificate of authority to establish and operate a health maintenance organization in this State has been issued or continued shall provide health care services to any enrollee for the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These health care services shall be provided to the same extent as for any other sickness.
- 7. This act shall take effect immediately and shall apply to service corporation contracts and health insurance policies in effect in this State on or after January 1, 1990 in which the service corporation, or insurer, as the case may be, has reserved the right to change the premium, and to health maintenance organizations operating in this State pursuant to a certificate of authority in effect on or after January 1, 1990 in which the health maintenance organization has reserved the right to change the schedule of charges for enrollee coverage.

3<u>2</u> 

22<sub>5</sub>

#### STATEMENT

This bill requires hospital service corporations (Blue Cross), medical service corporations (Blue Shield), health service corporations (Blue Cross/Blue Shield), commercial insurers and health maintenance organizations to provide benefits for the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational.

For this reason, this bill could be entitled the "Tishna Rollo Bill." Tishna Rollo is an eight-year old Glen Ridge girl who is battling Wilm's tumor, a rare form of cancer which affects the kidney and typically strikes young children. Recently, Tishna's

1 case has received much attention because her doctors have 2 concluded that the transplants are the one chance they have to 3 cure her disease, yet her family's health insurer has refused to 4 provide coverage for the treatment because it considers it 5 "experimental." In many cases, chemotherapy is effective in 6 treating Wilm's tumor. In those cases where it isn't successful, 7 the bone marrow transplants are an appropriate therapy which 8 allows doctors to save people who would not otherwise live. 9 Insurers will ordinarily pay for autologous transplants in the 10 treatment of leukemia and Hodgkin's disease, but regard the treatment as "experimental" in the treatment of hard tumors. 11 12 such as Wilm's tumor. This bill will eliminate the controversy surrounding the treatment and, in effect, absolve health insurers 13 14 of the responsibility of making any determination in this regard. 15 In so doing, it may spare other families the agony that Tishna 16 Rollo's family has endured. 17 18 19 **INSURANCE** 20 Requires health insurers to pay for bone marrow transplants in 21 22 treatment of Wilm's tumor.

unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the policy.

- 5. Every group health insurance policy providing hospital or medical expense benefits shall provides benefits to any named insured or other person covered thereunder for expenses incurred in the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These benefits shall be provided to the same extent as for any other sickness under the policy.
- 6. Notwithstanding any provision of law to the contrary, every health maintenance organization for which a certificate of authority to establish and operate a health maintenance organization in this State has been issued or continued shall provide health care services to any enrollee for the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational. These health care services shall be provided to the same extent as for any other sickness.
- 7. This act shall take effect immediately and shall apply to service corporation contracts and health insurance policies in effect in this State on or after January 1, 1990 in which the service corporation, or insurer, as the case may be, has reserved the right to change the premium, and to health maintenance organizations operating in this State pursuant to a certificate of authority in effect on or after January 1, 1990 in which the health maintenance organization has reserved the right to change the schedule of charges for enrollee coverage.

2.4

#### **STATEMENT**

 This bill requires hospital service corporations (Blue Cross), medical service corporations (Blue Shield), health service corporations (Blue Cross/Blue Shield), commercial insurers and health maintenance organizations to provide benefits for the treatment of Wilm's tumor, including autologous bone marrow transplants when standard chemotherapy treatment is unsuccessful, notwithstanding that any such treatment may be deemed experimental or investigational.

For this reason, this bill could be entitled the "Tishna Rollo Bill." Tishna Rollo is an eight-year old Glen Ridge girl who is battling Wilm's tumor, a rare form of cancer which affects the kidney and typically strikes young children. Recently, Tishna's

#### A3101

case has received much attention because her doctors have concluded that the transplants are the one chance they have to cure her disease, yet her family's health insurer has refused to provide coverage for the treatment because it considers it "experimental." In many cases, chemotherapy is effective in treating Wilm's tumor. In those cases where it isn't successful, the bone marrow transplants are an appropriate therapy which allows doctors to save people who would not otherwise live.

Insurers will ordinarily pay for autologous transplants in the treatment of leukemia and Hodgkin's disease, but regard the treatment as "experimental" in the treatment of hard tumors, such as Wilm's tumor. This bill will eliminate the controversy surrounding the treatment and, in effect, absolve health insurers of the responsibility of making any determination in this regard. In so doing, it may spare other families the agony that Tishna Rollo's family has endured.

#### **INSURANCE**

Requires health insurers to pay for bone marrow transplants in treatment of Wilm's tumor.

#### ASSEMBLY INSURANCE COMMITTEE

STATEMENT TO

# ASSEMBLY, No. 3101

## STATE OF NEW JERSEY

**DATED: MARCH 12, 1990** 

The Assembly Insurance Committee favorably reports Assembly Bill No. 3101.

This bill requires health service corporations (Blue Cross/Blue Shield of New Jersey), hospital service corporations (Blue Cross), medical service corporations (Blue Shield), commercial insurers and health maintenance organizations (HMO's) to provide benefits, to the same extent provided for any other sickness, for the treatment of Wilm's tumor, including autologous bone marrow transplants, when standard chemotherapy treatment is unsuccessful, regardless of whether such treatment is deemed experimental or investigational. The bill is applicable to those contracts and policies in effect in this State on or after January 1, 1990 in which the service corporation or insurer has reserved the right to change the premium and to HMO's operating in this State pursuant to a certificate of authority in effect on or after January 1, 1990 in which the HMO has reserved the right to change the schedule of charges for health care services provided to enrollees.

This bill has been referred to as the "Tishna Rollo Bill." Tishna Rollo is an eight-year old Glen Ridge girl who is battling Wilm's tumor, a rare form of cancer which generally affects the kidneys before spreading to other parts of the body. Recently, Tishna's case has received much attention because her doctors have concluded that the transplants are the one chance they have to cure her disease, yet her family's health insurer initially refused to provide coverage for the treatment because it asserted that such treatment was not covered in her health insurance contract as it is considered "experimental" or "investigational." Court action on the issue is pending. This bill will eliminate the controversy surrounding the treatment and, in effect, absolve health insurers, and ultimately the courts, of the responsibility of making any determination regarding this issue.